Market PotentialConsidering the large market potential, a well-thought-out OLC commercial strategy, and committed funding from accredited investors, UNCY is attractive to a long-term investor.
Patient PreferenceA greater preference for OLC is observed, with 79% of patients preferring it over their previous treatments.
Regulatory ApprovalOLC's FDA approval is expected by its PDUFA date, affirming a buy recommendation.